EGRX STOCKHOLDERS: Robbins LLP Reminds Eagle Pharmaceuticals Shareholders of Pending Lead Plaintiff Deadline – February 9, 2024
26 janv. 2024 12h33 HE
|
Robbins LLP
Eagle Pharmaceuticals, Inc. (EGRX) Misled Investors and Overstated its Revenue
Kaplan Fox & Kilsheimer LLP Reminds Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline
30 déc. 2023 11h00 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP Reminds Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline
Eagle Pharmaceuticals Shareholders Still Have Time to Participate in the EGRX Class Action; Contact Robbins LLP Today
29 déc. 2023 08h00 HE
|
Robbins LLP
Eagle Pharmaceuticals, Inc. (EGRX) Misled Investors and Overstated its Revenue
EGRX Alert: Kaplan Fox & Kilsheimer LLP Notifies Eagle Pharmaceuticals Investors of a Class Action and Highlights Upcoming Deadline
21 déc. 2023 13h53 HE
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired Eagle...
EGRX Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Eagle Pharmaceuticals, Inc. Class Action
18 déc. 2023 15h12 HE
|
Robbins LLP
Eagle Pharmaceuticals, Inc. (EGRX) Misled Investors and Overstated its Revenue
Kaplan Fox & Kilsheimer LLP Reminds Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline
17 déc. 2023 08h01 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox alerts investors of class action and upcoming deadline.
Eagle Pharmaceuticals Investor Update: Kaplan Fox & Kilsheimer LLP Notifies Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline
13 déc. 2023 12h30 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox notifies investors of Class Action filed against Eagle Pharmaceuticals.
Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX)
12 déc. 2023 00h42 HE
|
Robbins LLP
Eagle Pharmaceuticals, Inc. (EGRX) Misled Investors and Overstated its Revenue
EGRX Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
07 déc. 2023 08h00 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased securities of Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors: Please contact the Portnoy Law Firm to recover your losses
05 déc. 2023 15h59 HE
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Eagle Pharmaceuticals, Inc....